

AZD1152

# STUDY 9

In leukemia

A phase II clinical trial studying the efficacy, safety, and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in Acute Myeloid Leukemia (AML) patients

**Purpose:** To assess the efficacy, safety, and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients

**Primary endpoint:** Overall Complete Response Rate: Defined as the proportion of patients achieving a complete remission or complete remission with incomplete recovery of neutrophils and platelets

**Secondary endpoints:** To assess the safety and tolerability of AZD1152, alone and in combination with LDAC, compared to LDAC alone

**Participating countries:** Assessment of overall survival, duration of response, disease free survival, and time to complete response

Australia | France | Germany | Italy | Japan | Spain |  
United Kingdom | United States

*AZD1152 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.*

For more information,  
please contact:

Cancer Study Locator service, sponsored by  
AstraZeneca at 1-877-400-4656  
Or via e-mail at: [astrazeneca@emergingmed.com](mailto:astrazeneca@emergingmed.com)  
To find available investigator site details, go to: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

AstraZeneca 

AstraZeneca Pharmaceuticals, LP  
Wilmington, Delaware  
[www.astrazeneca.com](http://www.astrazeneca.com)